• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ResMed (RMD) Could Be 9% Undervalued As Earnings Beat And Guidance Hold

    Simply Wall St·11/01/2026 04:44:30
    语音播报

    ResMed (RMD) just turned in a stronger than expected first quarter for fiscal 2027, pairing that earnings beat with reaffirmed full year guidance and fresh capital returns through ongoing share repurchases.

    Despite the strong quarter and a fresh dividend of $0.66 per share, ResMed’s recent trading tells a mixed story. The share price has fallen around 9% over the past day and week, yet posted a 5% 30-day and nearly 7% 90-day share price return as momentum cooled from earlier gains.

    Scan beyond ResMed to see which peers show similar earnings strength and capital returns across 34 healthcare AI stocks.

    ResMed now trades below both analyst targets and one fair value estimate, even after stronger earnings and capital returns. Is the recent pullback a sensible margin of safety, or is it a warning the market is heeding?

    Most Popular Narrative: 9% Undervalued

    On the narrative view, ResMed’s fair value sits at $252.69 using a 7.57% discount rate, compared with a last close of $229.94. This frames the recent pullback as a potential valuation gap rather than a clean verdict on the latest quarter.

    Supply chain productivity initiatives that have already widened gross margin by roughly 500 to 600 basis points in three years, combined with modest price increases and guidance for low double digit basis point margin improvement each year through 2030, point to an ongoing structural lift to gross margin and free cash flow.

    See why 78 investors see ResMed as 9% undervalued.

    Result: Fair Value of $252.69 (UNDERVALUED)

    Still, this storyline can crack if the Astral corrective action drags on costs, or if inflation in key components keeps pressuring ResMed’s gross margin assumptions.

    Find out about the key risks to this ResMed narrative.

    Next Steps

    If this all feels mixed, that is the point, and it is why ResMed deserves a closer look using your own notes and analysis. To see what investors currently view as the bright spots, go straight to the 4 key rewards.

    Looking for more investment ideas beyond ResMed?

    If ResMed has you rethinking your watchlist, do not stop here. Broaden your field of vision and let fresh ideas challenge your current portfolio anchors.